Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

[影音] 避免惡性腦瘤復發 花慈研發技轉造福患者

惡性腦瘤治療,最新契機,花蓮慈濟醫學中心將技術技轉給長弘生物科技公司,研發出的貼片 (Cerebraca® Wafer),也就是當歸中的化學合成小分子,成功抑制腫瘤生長。 花蓮慈濟醫學中心院長 林欣榮:「開刀的時候因為有一些殘存的細胞在那裡, 我們怎麼辦,所以就用當歸西藥的貼片 (Cerebraca® Wafer),開完刀就直接貼在腦瘤的表面。」 第四期惡性腦瘤,高復發率,平均壽命四個月,透過老鼠試驗,相較傳統藥物,存活天數多出26天,而且能抑制癌細胞增生,並且促進凋亡,未來可開發成標靶或口服藥上市。